Change in special authority criteria for diabetes medicines
PHARMAC is changing the Special Authority criteria for empagliflozin and GLP-1 agonists, removing cardiovascular or renal risk as a requirement and widening access based primarily on HbA1c control and treatment pathways. Practices are encouraged to familiarise themselves with the new criteria, ensure required treatment trials are documented, and note that existing funded patients will retain access.
Read more